Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s DiseaseSHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) -- Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, patient-accessible therapeutics, today announced the initiation of a Phase 2 clinical study in China of RP902, an oral small-molecule drug developed to address significant unmet medical needs in patients with Alzheimer's disease.
